Optimal induction and post-remission therapy for AML in first remission.

@article{Rowe2009OptimalIA,
  title={Optimal induction and post-remission therapy for AML in first remission.},
  author={Jacob M. Rowe},
  journal={Hematology. American Society of Hematology. Education Program},
  year={2009},
  pages={396-405}
}
Approximately 300,000 patients in the world are diagnosed annually with acute myeloid leukemia (AML). The median age at presentation has been steadily increasing over the past few decades and now is approaching 70 years. Although considerable progress has been made over the past 3 decades in the therapy of AML, two thirds of young adults still die of their… CONTINUE READING